130 related articles for article (PubMed ID: 15494296)
21. Myelodysplasia: when to treat and how.
Larson RA
Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
[TBL] [Abstract][Full Text] [Related]
22. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Tohyama K
Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies in myelodysplastic syndrome.
Melchert M; List A
Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
[TBL] [Abstract][Full Text] [Related]
24. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
25. Modulation of angiogenesis in patients with myelodysplastic syndrome.
Estey EH
Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for the treatment of myelodysplastic syndrome.
Nivatpumin PJ; Gore SD
Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330
[TBL] [Abstract][Full Text] [Related]
27. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
28. Risk-based management of myelodysplastic syndrome.
Steensma DP; Tefferi A
Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
[TBL] [Abstract][Full Text] [Related]
29. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
Ørskov AD; Grønbæk K
Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
[TBL] [Abstract][Full Text] [Related]
30. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
31. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
List AF
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
[TBL] [Abstract][Full Text] [Related]
32. Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.
Odenike O
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):460-469. PubMed ID: 29222294
[TBL] [Abstract][Full Text] [Related]
33. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.
Gore SD
Hematology Am Soc Hematol Educ Program; 2011; 2011():550-5. PubMed ID: 22160088
[TBL] [Abstract][Full Text] [Related]
34. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes.
List AF
Forum (Genova); 1999; 9(1):35-45. PubMed ID: 10101209
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors in myelodysplastic syndrome.
Bhalla K; List A
Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
[TBL] [Abstract][Full Text] [Related]
38. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in myelodysplastic syndromes.
Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
[TBL] [Abstract][Full Text] [Related]
40. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
